Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
Preclinical data suggests GLP-1 therapies may accelerate late-life decline through lean mass loss and sarcopenic phenotype, particularly after treatment cessation. The research frames body composition preservation—not weight reduction alone—as central to longevity outcomes in obesity management.
A neuron-specific protein disposal mechanism called the membranal proteasome has been identified as a key player in tau aggregation and Alzheimer's pathology. This finding reframes neurodegeneration not as a mutation problem but as a failure in cellular quality control, with direct implications for how protein misfolding accumulates in the aging brain.
Environmental chemical exposures—the exposome—now explain mortality variation better than genetics, yet remain largely unmeasured in population health studies. Systematic quantification of synthetic chemicals in biobank samples could identify disease drivers and inform large-scale risk reduction.
FibroBiologics has initiated a Phase 1/2 trial of CYWC628, a fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers, enrolling up to 120 patients across Australian sites. The study will assess safety, tolerability, and efficacy compared with standard care alone, with interim analysis at six weeks to evaluate wound healing and safety endpoints.
Alnylam and Inceptive have partnered to use generative AI models to accelerate RNA interference drug design, leveraging two decades of proprietary siRNA data and six approved therapeutics. This collaboration demonstrates how machine learning can compress drug development timelines by identifying optimal molecular candidates from biological datasets, with potential applications across multiple therapeutic areas.
Longeveron is advancing laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young donor bone marrow, across four clinical indications including hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's licensing strategy at BIO 2026 signals movement toward commercialization of a cellular therapy platform with demonstrated efficacy signals across multiple disease states.
Magnesium functions as a central regulator of mitochondrial ATP production and metabolic resilience, with age-related declines in cellular magnesium contributing to insulin resistance, metabolic inflexibility, and accelerated aging. This positions magnesium homeostasis as a mechanistic checkpoint linking energy production capacity to disease risk and longevity.
Surgery impairs memory and brain cell regeneration in aged mice by disrupting cholinergic signaling from the medial septum to the hippocampus. Restoring this pathway through pharmacological or sustained neural activation reverses both cognitive and neurogenic deficits, suggesting a tractable mechanism for postoperative cognitive dysfunction.
Aged skeletal muscle exhibits an exaggerated mitochondrial unfolded protein response to physical stress, driven by reduced protein-folding capacity and elevated reactive oxygen species signaling. This amplified stress response reflects compromised mitochondrial resilience and suggests potential targets for preserving muscle function during aging.
Lifelong time-restricted feeding extended healthspan in mice on standard diets, with distinct sex-specific effects on aging pathologies and lifespan. This finding suggests temporal eating patterns influence fundamental aging processes independent of caloric restriction or weight loss.
Mechanical stress suppresses miR-330 expression in cartilage and bone, driving osteoarthritis progression through increased inflammation and cell death. Restoring miR-330 via gene therapy protects against load-induced cartilage and bone degeneration in animal models, suggesting a tractable target for preventing occupational and age-related joint disease.